# CURRICULUM VITAE

**NAME**: **Prashanth R. Sunkureddi, M.D**. **DATE**: January 2019

## PRESENT POSITION AND ADDRESS:

Prashanth Sunkureddi, M.D., P.A.
Texas Rheumatology
2006 – Present
3725 E. League City Pkwy #200
League City, Tx 77573
Ph. 281-957-9127 /F. 281-957-9157
Website: www.texasrheumatology.com
Email: DrSunkureddi@texasrheumatology.com

Clinical Assistant Professor of Medicine
Division of Rheumatology
The University of Texas Medical Branch
301 University Blvd-Route 1165
Galveston, Texas 77555-0759

Accurate Clinical Research, Inc.
Medical Director and Investigator
Jan. 01, 2009 – Present
3725 E. League City Parkway, Suite 200
League City, TX 77573

Board of Directors, State of Texas Association of Rheumatologists (STAR) (2018-Present)

## CERTIFICATION

| | |
|---|---|
| Board Certification: | Board Certified in Rheumatology<br>Initial Certification: November 2006<br>Recertification: November 2016 |
| | Board Certified in Internal Medicine<br>Initial Certification: August 2004<br>Recertification: November 2014 |

**EDUCATION**

| | |
|---|---|
| Fellowship: | Rheumatology<br>The University of Texas Medical Branch<br>Galveston, Texas 77555<br>July 2004-June 2006 |
| Internship & Residency: | Internal Medicine<br>The University of Texas Medical Branch<br>Galveston, Texas 77555<br>June 2001-June 2004 |
| Medical School: | St. George's University School of Medicine<br>Grenada, West Indies<br>Doctor of Medicine, May 2001 |
| Undergraduate: | Baylor University<br>Waco, Texas<br>Bachelor of Arts in Biology, May 1995 |

**PROFESSIONAL MEMBERSHIPS:**

Member- American College of Rheumatology
Member-American College of Physicians
Member-American Medical Association
Member-Texas Medical Association
Member-Galveston County Medical Society

**LICENSURE:**

State of Texas- M1374

**HOSPITAL PRIVILIGES:**

Courtesy Privileges, Houston Methodist St. John Hospital, Nassau Bay, Texas

**HONORS AND AWARDS:**

Bone Bash Medical Honoree, Arthritis Foundation,
2018 "Five Star Award" 2011, USFHP Insurance Plan
Winner, 2006 Distinguished Fellow Award, American College of Rheumatology
Winner, James W. McLaughlin Travel Award, 2006 Annual IHII/McLaughlin Colloquium on Infections and Immunity, UTMB, January 2006
"Superior Performance" - Rheumatology Fellowship Evaluation
"Superior Performance" - Internal Medicine Residency Evaluation

Iota Epsilon Alpha, International Medical Honors Society, St. George's University

Dean's List, St. George's University School of Medicine

**COMMUNITY SERVICE/TEACHING:**

Past Sponsor for Arthritis Foundation (Texas Chapter):
Bay Area Arthritis Walk;

Volunteer Attending- St.Vincent's Free Student Clinic, Galveston, Texas

Preceptor for Community rotations for Medical students, Residents and Fellows;

Committee Member, Capstone Project for Mark Jacques, MD MPH candidate at UTMB; "Gout: An Aeromedical Clinical Practice Guideline", 2008

Attending Faculty, UTMB Rheumatology. 2006-2009;

Adjunct Faculty, UTMB Rheumatology. 2009-Present

**LECTURES/TALKS/PRESENTATIONS:**

Speaker's Bureau: Eli Lilly, Novartis, Pfizer, Bristol Myers Squibb, UCB, Amgen, AbbVie, Horizon Pharma, Crescendo Bioscience, Janssen

"Fibro my What?-Understanding Fibromyalgia". Christus St.John Hospital, Live Well Conference, May 2012.

"My Achy, Breaky Bones" Christus St. John Hospital, Live Well Conference, 2011, 2014

"Understanding Osteoporosis", Freeman Library, Houston, Texas, May 2011

"Rheumatoid Arthritis", YMCA, Houston, Texas. March 2010

"Lupus", Health Occupations Students of America Club, Clear Springs High School, League City, Texas. Jan 2010

"Rheumatoid Arthritis", Public Education Event, November, 2009; Hobby Marriott Hotel, Houston, Texas

"Understanding Arthritis", November 2009, Freeman Library, Houston, Texas

"Immunopathogenesis and Immunotherapies of Rheumatic Disease", Division of Allergy and Immunology Grand Rounds, UTMB, Galveston, Texas 2009

Speaker: Arthritis Foundation Community Education Forums, Christus St. John Stroke Support Group

Panelist, “Let’s Talk RA”, Community Arthritis Education Forum, April, 2008. Houston, Texas

“Joint Hypermobility Syndrome”, Ehlers-Danlos National Foundation, Annual Meeting, Houston, Texas. July 2007

“Current Concepts in Rheumatoid Arthritis” CME presentation, Christus St. John Hospital, Nassau Bay, Texas; December 2006

“Understanding Rheumatoid Arthritis”, UTMB Senior Citizen Outreach Program, La Marque, Texas, May 2006

Faculty Lecturer, “Pediatric Rheumatology Board Review for Pediatricians”, The Osler Institute, Terre Haute, Indiana

## CLINICAL TRIALS

Principal Investigator, 2018 UCB RA0098, A Multicenter, Open-Label Study To Evaluate The Safe And Effective Use Of An Electro-Mechanical Injection Device (E-Device) For The Subcutaneous Self-Injection of Certolizumab Pegol Solution By Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, Or Moderately to Severely Active Crohn’s Disease

Principal Investigator 2018 Eli-Lilly, I8K-MC-JPDA: A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study to Evaluate the Safety and Efficacy of LY3337641 in Adult Subjects With Rheumatoid Arthritis: The RAjuvenate Study

Principal Investigator, 2018: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination with Rituximab to Adult Subjects with Systemic Lupus Erythematosus (SLE).

Principal Investigator, 2018 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RO7123520 AS ADJUNCT TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO TNF-α

Principal Investigator, 2017: A Randomized, Double-Blind Study To Compare Pharmacokinetics and Pharmacodynamics, Efficacy And Safety Of ABP-798 With Rituximab In Subjects With Moderate To Severe Rheumatoid Arthritis

Principal Investigator, 2017: A Randomized, Double-Blind Phase 3 Study To Assess The Efficacy And Safety Of ABP 710 Compared To Infliximab In Subjects With Moderate To Severe Rheumatoid Arthritis

Principal Investigator, 2016: A Study to Assess the Dosing Robustness of the CHS-1420 Autoinjector in Subjects with Rheumatoid Arthritis

Principal Investigator, 2016: Prospective Outcomes Study: Vectra® DA Guided Care Compared to Usual Care

Principal Investigator**,** 2016: Comparative and Pragmatic Study of Simponi Aria versus Remicade in Rheumatoid Arthritis

Principal Investigator, 2016: A Randomized, Double-Blind, Multicenter, 3-Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients with Rheumatoid Arthritis

Principal Investigator, 2016: A phase 3b/4 randomized double blind placebo controlled study of methotrexate (MTX) withdrawal in subjects with rheumatoid arthritis (RA) treated with tofacitinib 11mg modified release (mr) formulation

Principal Investigator, 2016: A 12 week randomized, double-blind, double dummy, parallel group, active and placebo-controlled, multicenter study to assess the efficacy and safety profile of pf-06650833 in subjects with active rheumatoid arthritis with an inadequate response to methotrexate

Principal Investigator, 2016: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy

Principal Investigator, 2016 R-Pharm CL04041023: A Randomized, Double Blind, Parallel Group, Placebo and Active Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy

Principal Investigator, 2016 Boehringer Ingelheim 1297.3: Long-term assessment of safety, efficacy, pharmacokinetics and immunogenicity of BI 695501 in patients with rheumatoid arthritis (RA):

Principal Investigator, 2015 Boehringer Ingelheim BI1297.11: Assessment of real-life patient handling experience of BI 695501 administered subcutaneously with an autoinjector in patients with rheumatoid arthritis: an open-label, interventional clinical trial followed by an extension phase of BI 695501 administered with a prefilled syringe.

Principal Investigator, 2015 Boehringer Ingelheim BI1297.2: Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial

Principal Investigator, 2015 Janssen 42160443PAI3007: Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Fulranumab as Adjunctive Therapy in Subjects with Signs and Symptoms of Osteoarthritis of the Hip or Knee

Principal Investigator, 2015: A Phase 3 Randomzied, Double- Blind Study Assessing the Efficacy and Safety of PF-06438179 and Infliximab in Combination with Methotrexate in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate

Principal Investigator, 2015: Chorus I5Q-MC-CGAF: A Phase 2, Randomized, Double-Blind, Placebo and Active- Controlled Trial of LY2951742 In Patients with Mild to Moderate Osteoarthritis Pain of the Knee

Principal Investigator, 2015: A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated with or without Benlysta (belumumab)

Principal Investigator, 2015: A Multi-Center, Randomized, Double- Bind, Placebo-Controlled 24- Week Study Followed by Long- Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease- Modifying Antirheumatic Drug-Experienced Patients with Active Psoriatic Arthritis

Principal Investigator, 2014: A Phase 2, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects with Gout and Moderate Renal Impairment

Principal Investigator, 2014: Phase 3b/4 Randomized Safety Endpoint Study Of 2 Doses Of Tofacitinib In Comparison To A Tumor Necrosis Factor (Tnf) Inhibitor In Subjects With Rheumatoid Arthritis

Principal Investigator, 2014: MSC12665 (SARIL-RA-EASY): A multicenter, randomized, open-label, parallel-group usability study of the sarilumab auto-injector device and a prefilled syringe in patients with moderate to severe active rheumatoid arthritis who are candidates for anti-IL6R therapy

Principal Investigator, 2014: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 Given with Methotrexate (MTX) in Subjects with Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Anti-TNF Biologic Therapy

Principal Investigator, 2013: A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104)

in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy

Principal Investigator, 2013: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors

Principal Investigator, 2013: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs with Moderately to Severely Active Rheumatoid Arthritis

Principal Investigator, 2013: A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Rheumatoid Arthritis

Principal Investigator, 2012: A 24-week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy with 104-Week Open Label Extension

Principal Investigator, 2012: A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients with Rheumatoid Arthritis

Principal Investigator, 2012: A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium (FosD) in the Treatment of Rheumatoid Arthritis

Principal Investigator, 2012: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination with Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naïve Adults with Early Active Rheumatoid Arthritis

Principal Investigator, 2012: A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects with Gout who have had an Inadequate Hypouricemic Response to Standard of Care Allopurinol

Principal Investigator, 2011: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess The Long Term Safety, Tolerability and Efficacy Up To 2 Years in Patients with Active Psoriatic Arthritis

Principal Investigator, 2011: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the

Safety, Tolerability and Long Term Efficacy up to 2 Years in Patients with Active Rheumatoid Arthritis who have an Inadequate Response to Anti-TNFα Agents

Principal Investigator, 2011: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Systemic Lupus Erythematosus (SLE)

Principal Investigator, 2011: A Phase 3, 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg S.C. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients

Principal Investigator, 2011: A Phase 3, A Randomized, Double-Blind, Active-Controlled Study of Canakinumab (ACZ885) Pre-Filled Syringes or Reconstituted Lyophilizate Versus Triamcinolone Acetonide for Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients.

Principal Investigator, 2011: A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA)

Principal Investigator, 2011: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE).

Principal Investigator, 2011: A Phase 4, Multicenter, Randomized, 52-Week Study to Evaluate the Routine Assessment of Patient Index Data (Rapid3) Compared to the Clinical Disease Activity Index (CDAI) to Prospectively Predict Treatment Success at 52 Weeks Based on a Treatment Decision at Week 12 in Subjects with Moderate to Severe Rheumatoid Arthritis Receiving Certolizumab Pegol (CZP)

Principal Investigator, 2011: A Phase 3, Randomized, double-blind, parallel-group study of safety and the effect on clinical outcome of tocilizumab SC versus placebo SC in combination with traditional disease modifying anti-rheumatic drugs (DMARDs) in patients with moderate to severe active rheumatoid arthritis

Principal Investigator, 2011: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to Methotrexate Therapy

Principal Investigator, 2011: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) with or without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy

Principal Investigator, 2011: A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects with Active Rheumatoid Arthritis Who Completed Study RA0056

Principal Investigator, 2010: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study with an Active Comparator to Evaluate the Efficacy and Safety of CDP6038 Administered Subcutaneously for 12 Weeks to Subjects with Active Rheumatoid Arthritis Having Previously Failed TNF–Blocker Therapy

Principal Investigator, 2010: A Phase 2, Multi-center, Randomized, Parallel Group, Double-blind, MTX Controlled Study to Assess the Clinical Efficacy, Safety and Tolerability of CH-4051 in Patients With Active RA Who Have Shown an Inadequate Response to MTX Monotherapy

Principal Investigator, 2010: A Phase 3, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Participants With Rheumatoid Arthritis

Principal Investigator, 2010: A Phase 3b, Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects with Gout and Cardiovascular Comorbidities.

Principal Investigator, 2010: A Phase 3, Randomized, Controlled Study of ACZ885 (Canakinumab) on the Treatment and Prevention of Gout Flares in Patients with Frequent Flares for Whom NSAIDS and/or Colchicine are Contraindicated, Not Tolerated or Ineffective.

Principal Investigator, 2010: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Analgesic Efficacy and Safety of Subcutaneous Administration of Tanezumab in Patients with Osteoarthritis of the Knee.

Principal Investigator, 2009: Application of Methotrexate Optimization in Rheumatoid Arthritis.

Sub-Investigator, 2009: A Phase 3b, Multicenter Study with a 12-Week Double-Blind, Placebo-Controlled, Randomized Period Followed By an Open-Label, Extension Phase to Evaluate the Safety And Efficacy of Certolizumab Pegol Administered to Patients with Active Rheumatoid Arthritis. Phillip Waller, MD and Accurate Clinical Research.

Sub-Investigator, 2009: A Phase 4, Multicenter, Open-Label, Assessor-Blinded, Switch Study of the Efficacy and Safety of Infliximab (REMICADE) in Patients with Active Rheumatoid Arthritis Who Are Responding Inadequately to Etanercept (ENBREL) or Adalimumab (HUMIRA).

Sub-Investigator, 2009: A Phase 3, Multicenter, Randomized, Double-Blind, Controlled Study of the Long Term Analgesic Efficacy and Safety of Tanezumab

Alone or in Combination with Nsaids Versus Nsaids Alone in Patients with Osteoarthritis of the Knee or Hip.

Co-Investigator, 2005: A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept in Subjects with Active Rheumatoid Arthritis on Background Non-Biologic DMARDs who have an Inadequate Response to Anti-TNF Therapy and have Limited Therapeutic Options. UTMB.

**PUBLICATIONS:**

**P Sunkureddi,** D Latremouille-Viau, M Meiselbach, J Xie, P Hur, R Joshi Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review. Rheumatology Therpaeutics 2019

R Joshi, D Latremouille-Viau, M Meiselbach, J Xie, Y Park, **P Sunkureddi** Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review. Drugs Real World Outcomes. 2019

**P Sunkureddi**, S Doogan, J Heid, S Benosman, A Ogdie, L Martin, J Palmer. Evaluation of Self-reported Patient Experiences: Insights from Digital Patient Communities in Psoriatic Arthritis. The Journal of Rheumatology 2018; 45:4

**P Sunkureddi**, D Gibson, S Doogan, J Heid, S Benosman, Y Park. Using Self-Reported Patient Experiences to Understand Patient Burden: Learnings from Digital Patient Communities in Ankylosing Spondylitis. Advances in Therapy 2018

Cronstein N, **Sunkureddi P**. Mechanistic Aspects of Inflammation and Clinical Management of Inflammation in Acute Gouty Arthritis. Journal of Clinical Rheumatology 2013;19: 19-29)

**Sunkureddi,P. Gouty Arthritis:** Understanding the Disease State and Management Options in Primary Care. Advances in Therapy: *September 2011*.

Kumar S, Pappalardo E, Gonzales EB, **Sunkureddi P**, Pierangeli S. Isolated Elevation of IgA Anti-Beta 2Glycoprotein I Antibodies with Manifestations of Antiphospholipid Syndrome (APS): A case series of four patients. Lupus. *October 2009 18(11):1011-4*.

Eisenberg M**, Sunkureddi P,** McNearney T, Gonzalez EB. Unusual occurrence of Renal Cell Carcinoma diagnosed in two young Hispanic patients with diffuse systemic sclerosis. Journal of Clinical Rheumatology. *December 2007: 13(6): 363-364.*

Karnath B, **Sunkureddi P**. Extra-intestinal manifestations of hepatogastrointestinal disease. Hospital Physician. *July 2006:42(7);51-56*

**Sunkureddi P,** Contreras J, Eisenberg M,. Photo Dx: Hand pain and swelling in a 63 year old woman. The Journal of Musculoskeletal Medicine. *April 2006:23(4);282-284*

**Sunkureddi P**, Karnath B, Nguyen-Oghalai T. Clinical signs of Gout. Hospital Physician. *January 2006:42(1);39-42,47*

**Sunkureddi P**, Gonzalez EB, Washington R et al. A 39 year old man with chest pain: Cardiovascular manifestations of systemic lupus erythematosus. Cleveland Clinic Journal of Medicine. *November 2005:72(11);1050-56*

**Sunkureddi P**, Baethge B. Eosinophilic gastroenteritis associated with systemic Lupus erythematosus. The Journal of Clinical Gastroenterology. (Letter to the Editor). *Oct 2005; 39(9):838-9*

**Sunkureddi P**, Baethge B. et al. Eosinophilic enteritis associated with systemic lupus erythematosus. Southern Medical Journal. *October 2005;98(10):1049-52*

**Sunkureddi P,** Kumar S, Baethge B. Photo Dx: Persistent Pain and Swelling after an Insect Bite.The Journal of Musculoskeletal Medicine. *August 2005:22(8);417-419*

**Sunkureddi P**, Nguyen-Oghalai T, Jarvis J, Karnath B. Clinical Signs of Dermatomyositis. Hospital Physician. *April 2005:41(3);41-44*

**ABSTRACTS/POSTERS**

**P. Sunkureddi**, Baojin Zhu, Alexis Ogdie, Aubrey Spraberry, Jeffrey Lisse, Chen-Yen Lin and David Shrom. Ixekizumab Treatment Results in Rapid and Sustained Improvements in the Disease Activity Index for Psoriatic Arthritis (DAPSA) in Patients Naïve to Biologic Dmards or with Previous Inadequate Response to TNF Inhibitors. American College of Rheumatology Annual Meeting. Chicago, IL 2018

Alexis Ogdie, **P. Sunkureddi**, Baojin Zhu, Aubrey Spraberry, William Malatestinic, Yan Dong and David Shrom. Relative Contributions of Improvements in the Psoriasis Area and Severity Index (PASI) and Disease Activity Index for Psoriatic Arthritis (DAPSA) to Improvements in Quality of Life and Function in Patients with Psoriatic Arthritis. American College of Rheumatology Annual Meeting. Chicago, IL 2018

J Smolen, **P Sunkureddi,** J Anderson, J Griffith, D Jiang, K Chen, J Suboticki, A Kavanaugh. The Ability of patients with early Rheumatoid Arthritis to taper low dose

glucocorticoids on Methotrexate monotherapy and in combination with Adalimumab. American College of Rheumatology Annual Meeting. San Diego, CA 2017

A Kavanaugh, RF van Vollenhoven, **P Sunkureddi**, Y Zhang, J Suboticki, J Smolen. Disease flares among early RA patients treated with continued Methotrexate either alone or in combination with Adalimumab. American College of Rheumatology Annual Meeting. San Diego, CA 2017

S. Schwartzman, **P. Sunkureddi** , L. Takiya , M. Snyder , H. Fan, T. Lukic, J. Roberts , W. F. C. Rigby. Comparison of tofacitinib efficacy in patients with moderate vs severe rheumatoid arthritits: pooled analysis of phase 3 studies. European League Against Rheumatism Annual Meeting (EULAR). Madrid, Spain 2017

**P Sunkureddi**, D Gibson, S Doogan, J Heid, S Benosman, Y Park. Using self-reported patient experiences to understand patient burden: Learnings from digital patient communities in Ankylosing Spondylitis. American College of Rheumatology Annual Meeting, Washington D.C. 2016

S Doogan, J Heid, S Benosman, A Ogdie-Beatty, L Martin, **P Sunkureddi**, J Palmer. Using self-reported patient experiences to understand patient burden: Learnings from digital patient communities in Ankylosing Spondylitis. American College of Rheumatology Annual Meeting, Washington D.C. 2016

A Kavanaugh, B Haraoui, **P Sunkureddi**, B Wolfe, L Wang, J Suboticki and E Keystone. The Relationship between Elevations in CRP with Physical Function and Radiographic Progression Over the Long-term in Patients with Rheumatoid Arthritis; American College of Rheumatology Annual meeting, Washington, D.C. 2016

**P.Sunkureddi**, R. Möricke , E. Toth , J. P. Brown , U. Machein , K. Lheritier, G. Junge, A. Kivitz. Canakinumab liquid formulation in acute gouty arthritis patients: Long term safety and efficacy results from a 36 week extension study. American college of Rheumatology Annual Scientific Meeting, San Francisco, CA 2015.

R. Möricke **, P. Sunkureddi** , E. Toth , J. P. Brown , U. Machein , K. Lheritier, G. Junge, A. Kivitz. Long term safety and maintenance of efficacy of Canakinumab liquid formulation in acute gouty arthritis patients: Results from a 36 week extension study. EULAR Abstract Supplement; Rome, 2015

**P Sunkureddi** ,E Toth, JP Brown, A Kivitz, A Stancati, D Richard, K Lheritier, R Möricke, A Kivitz.. Long Term safety and efficacy of canakinumab liquid formulation in acute gouty arthritis patients: Results from a 36 week extension study. American college of Rheumatology Annual Scientific Meeting, Boston, MA 2014

**P Sunkureddi** ,E Toth, JP Brown, A Kivitz, A Stancati, D Richard, K Lheritier, R Möricke.. Efficacy and safety of canakinumab pre-filled syringe in acute gouty arthritis patients with chronic kidney disease stage ≥3; A post hoc analysis of 12 week data.

American college of Rheumatology Annual Scientific Meeting, Boston, MA 2014

**P Sunkureddi** ,E Toth, JP Brown, A Kivitz, A Stancati, D Richard, K Lheritier, R Möricke. Canakinumab pre-filled syringe vs triamcinolone acetonide in the treatment of acute Gouty arthritis attacks: results from a post-hoc analysis in difficult-to-treat patients; EULAR Abstract Supplement; Paris, 2014

**P Sunkureddi** ,E Toth, JP Brown, A Kivitz, A Stancati, D Richard, K Lheritier, R Möricke. Efficacy and safety of canakinumab pre-filled syringe in acute gouty arthritis patients with chronic kidney disease stage ≥3; EULAR Abstract Supplement; Paris, 2014

**P Sunkureddi**. Efficacy and Safety Of Canakinumab Pre-Filled Syringe Versus Triamcinolone Acetonide In Acute Gouty Arthritis Patients. American college of Rheumatology Annual Scientific Meeting, San Diego, CA 2013

**P. Sunkureddi**, T. Bardin, R. Alten, N. Schlesinger, M. Bloch, T. Kiechle, G. Krammer, A. Sphilsky, A. So. Efficacy and safety of Canakinumab in Gouty Arthritis Patients with Chronic Kidney Disease Stage 3-5. European League against Rheumatism Annual Meeting (EULAR). June 2012; Berlin, Germany

**P Sunkureddi**, A So, T Bardin, R Alten, M Bloch, T Kiechle, G Krammer, A Shpilsky and N Schlesinger. Effect of IL-1[beta] Inhibition with Canakinumab Compared to Triamcinolone Acetonide on Pain Intensity and New Flares in Gouty Arthritis Patients with Chronic Kidney Disease Stage 2-5; Oral Presentation; American Society of Nephrology Annual Scientific Meeting, Philadelphia, PA 2011

**P. Sunkureddi**, T. Bardin, R. Alte[3], N. Schlesinger, M. Bloch, T. Kiechle, G. Krammer, A. Shpilsky, A. So. Effect of IL-1&beta inhibition with Canakinumab Compared to Triamcinolone Acetonide on Pain Intensity and New Flares in Gouty Arthritis Patients with Chronic Kidney Disease Stage 2-5. American College of Rheumatology Annual Scientific Meeting, Chicago, IL 2011

**Sunkureddi P**, Gendreau, J. Demographic, disease and treatment characteristics of the rheumatoid Arthritis population enrolled in the AMORA Study (Applications for Methotrexate Optimization in Rheumatoid Arthritis) in evaluating the Avise PG test. American College of Rheumatology Annual Scientific Meeting, Atlanta, GA 2010

Martinez LA, Valenzuela R, Seif AM, Papalardo E, Vilá LM, Najam S, McNearney TA, Gonzalez EB, **Sunkureddi P**, Binder WL, Reveille JD, Norman G, Shums Z, Alarcon GS and Pierangeli SS. Do Clinically Relevant IgA-Anti-B2glycoprotein I (anti-B2GPI) Antibodies Bind to Domain IV/V of β2GPI: American College of Rheumatology Annual Scientific Meeting, Philadelphia, PA 2009

Rezazadeh B, McNearney TM, Gonzalez EB, **Sunkureddi P**. Race/Ethnicity is more strongly associated with anti-ccp antibody titers than smoking in rheumatoid arthritis. American College of Rheumatology Annual Scientific Meeting, San Francisco, CA 2008

Kumar S, Gonzalez EB, Najam S, Pappalardo E, McNearney T, **Sunkureddi P**, Pierangeli SS. Isolated Elevation of IgA anti-Beta 2 Glycoprotein I antibodies with manifestations of anti-phospholipid antibody syndrome: A case series of five patients. Presented at the 6th International Congress on Autoimmunity, Porto, Portugal, September 2008

Gonzalez EB, McNearney TM, **Sunkureddi P**. Higher anti-ccp antibody titers and test sensitivity observed in non-Caucasians with rheumatoid arthritis. European League against Rheumatism Annual Meeting (EULAR), Barcelona, June 2007

**Sunkureddi P**, McNearney TM, Vasquez VT, Gonzalez, EB. Race/Ethnicity differences in anti-CCP antibody in patients with suspected rheumatoid arthritis. American College of Rheumatology Annual Scientific Meeting, San Diego, CA 2006. Arthritis & Rheumatism 2005;52(12):4095

Gonzalez EB, McNearney TM, Wollaston DE, **Sunkureddi P,** Lau DT. Prevalence of Hepatitis C infection in an autoantibody-positive population from a university-based rheumatology clinic. American College of Rheumatology Annual Scientific Meeting, San Diego, CA 2006. Arthritis & Rheumatism 2005;52(9):S96.